SynthesisBMC surgery2026
A systematic review and meta-analysis of early and long-term outcomes after endovascular interventions in patients with thromboangiitis obliterans and critical limb ischemia with GRADE assessment.
Synthesis in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThromboangiitis obliterans (TAO) is a rare inflammatory occlusive vascular disorder that affects small and medium-sized vessels and often progresses to critical limb ischemia (CLI). Although various treatments have been used in advanced stages, endovascular interventions have increasingly gained attention as a limb-saving therapy. Due to limited and varied evidence in published studies, this systematic review and meta-analysis evaluates the early and long-term outcomes of endovascular treatments in patients with TAO-related CLI.
methodThis systematic review and meta-analysis was conducted according to PRISMA guidelines and registered on PROSPERO (CRD420251089226). PubMed, Scopus, WOS, Embase, and Google Scholar databases were searched with relevant keywords up to July 2025. A total of 27 studies involving 1,217 patients were included. Pooled outcomes were estimated using a generalized linear mixed model (GLMM). Heterogeneity was assessed using the I² statistic, and potential publication bias was examined via funnel plots and Egger’s test.
resultsThe pooled technical success rate for endovascular procedures was 89%, with limb salvage rates of 94% at 6 months and 97% at 12 months. Primary patency was 56% at 6 months, 73% at 12 months, and 61% at 36 months; these findings highlight temporal variability, and cross-time comparisons should be interpreted with caution. Secondary patency was initially higher but also decreased over long-term follow-up. Restenosis rates were 15% early and 34% late. Major and minor amputation rates were 10% and 13%, respectively. No in-hospital mortality was reported.
conclusionsEndovascular therapy represents a safe and effective option for treating TAO-related CLI, especially in patients who are not candidates for surgery. While early results are promising, the loss of patency and rising restenosis over time highlight the importance of careful follow-up and proper patient selection. Our findings support a personalized, multidisciplinary approach to managing TAO and emphasize the vital role of smoking cessation in improving clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.